There are multiple phase 2 clinical trials using the CPP approach as a systemic or topical delivery system and these include NCT00451256 for c-myc (prevention of undesirable cell proliferation in coronary artery bypass grafts) and PsorBan for cyclosporine andmNCT007885954 for a PKCδ inhibitor (the treatment of acute myocardial infarction). This evidence concerns the gene MYC and myocardial infarction.